オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 200 mg - tablet - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 25 mg - tablet - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: disodium edetate; purified water; yellow beeswax; indigo carmine; butylated hydroxyanisole; brilliant scarlet 4r; dl-alpha-tocopherol; gelatin; soya oil; partially hydrogenated soya oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); titanium dioxide; hydrogenated vegetable oil - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects asssociated with its use. isotretinoin should be reversed for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: soya oil; dl-alpha-tocopherol; disodium edetate; butylated hydroxyanisole; partially hydrogenated soya oil; yellow beeswax; hydrogenated vegetable oil; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); brilliant scarlet 4r; iron oxide black; titanium dioxide; purified water - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. jene-35ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - valaciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; indigo carmine aluminium lake; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 6000; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. treatment of ophthalmic zoster. treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of > 15 ml/min. for the reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions). for prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - tramadol hydrochloride, quantity: 300 mg - tablet, modified release - excipient ingredients: povidone; polyvinyl acetate; colloidal anhydrous silica; hydrogenated vegetable oil; xanthan gum; hydroxypropyl distarch phosphate; magnesium stearate; sodium lauryl sulfate - indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. not indicated for use in chronic non-cancer pain other than in exceptional circumstances. not indicated as an as-needed (prn) analgesia.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - tramadol hydrochloride, quantity: 200 mg - tablet, modified release - excipient ingredients: hydrogenated vegetable oil; povidone; hydroxypropyl distarch phosphate; sodium lauryl sulfate; xanthan gum; magnesium stearate; polyvinyl acetate; colloidal anhydrous silica - indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. not indicated for use in chronic non-cancer pain other than in exceptional circumstances. not indicated as an as-needed (prn) analgesia.